570 results on '"Lim, Sun Min"'
Search Results
102. Patritumab Deruxtecan: Paving the Way for EGFR-TKI–Resistant NSCLC
103. SKI‐G‐801, an AXL kinase inhibitor, blocks metastasis through inducing anti‐tumor immune responses and potentiates anti‐PD‐1 therapy in mouse cancer models
104. Successful Rechallenge of Trastuzumab Deruxtecan After Drug-Induced Interstitial Lung Disease in a NSCLC With HER2 Mutation: A Case Report
105. Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience
106. A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
107. The promise of bispecific antibodies: Clinical applications and challenges
108. Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients
109. Impact of cumulative time on the clinical outcomes of endoscopic submucosal dissection in gastric neoplasm
110. Clinical decision support algorithm based on machine learning to assess the clinical response to anti–programmed death-1 therapy in patients with non–small-cell lung cancer
111. Abstract 1787: YH29407, a novel IDO1 inhibitor, enhances the anti-tumor effects through increased tumor-reactive T cell functions in solid tumor
112. Abstract 1471: Incorporation of SKI-G-801, novel AXL inhibitor, with anti-PD-1 inhibitor plus chemotherapy improved anti-tumor activity and survival outcome via enhancing anti-tumor T cell immunity
113. Abstract 1467: BLU-945, a fourth-generation, potent and highly selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with intracranial activity, demonstrates robust in vivo antitumor activity in models of osimertinib-resistant non-small cell lung cancer (NSCLC)
114. Abstract 1826: Comprehensive preclinical study on GI-101, a novel CD80-IgG4-IL2 variant protein, as a therapeutic antibody candidate with bispecific immuno-oncology target
115. Abstract 1106: BRAF and EGFR fusion as a novel mechanism of resistance mechanism to Lazertinib, 3rd- generation EGFR-TKI, in EGFR-mutant NSCLC
116. Abstract 2755: Single-cell RNA sequencing reveals priming professional antigen-presenting macrophages and chemokine expressing T cells in tumor microenvironment by AXL inhibitor, SKI-G-801
117. Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
118. Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma
119. Brief Report: Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib
120. Liver Stiffness Measurement Using Acoustic Radiation Force Impulse (ARFI) Elastography and Effect of Necroinflammation
121. Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study
122. Interim analysis for window of opportunity trial of single dose preoperative durvalumab (D) with or without tremelimumab (T) for operable head and neck squamous cell carcinoma (HNSCC).
123. Broad-Spectrum Antibiotic Regimen Affects Survival in Patients Receiving Nivolumab for Non-Small Cell Lung Cancer
124. Sequencing of MET Inhibitors in Lung Cancer: Have We Met the Target?
125. Additional file 1 of Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer
126. Additional file 2 of Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer
127. Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma
128. The Next Target for NSCLC: Let It Be “RET”
129. Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience.
130. PhaseIIstudy of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma:KCSG‐LU16‐07
131. AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation
132. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC
133. Prognostic Value of CD200R1 mRNA Expression in Head and Neck Squamous Cell Carcinoma
134. Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer
135. Real World Experience of Nivolumab in Non-Small Cell Lung Cancer in Korea
136. Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives
137. Predicting treatment outcomes using 18 F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy.
138. Association between Blood Pressure and Carotid Intima-Media Thickness
139. Abstract 4076: Finding the optimal strategy of incorporating immune checkpoint inhibitor inALK-positive non-small-cell lung cancer usingEML4-ALKtransgenic mouse model
140. Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinoma
141. Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma
142. Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
143. Sonic Hedgehog Pathway as the Prognostic Marker in Patients with Extensive Stage Small Cell Lung Cancer
144. Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models
145. Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG‐LU16‐07.
146. Abstract 1148: Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models
147. Can We Prevent Resistance to Osimertinib? Combination or Sequential
148. Investigating the feasibility of targeted next-generation sequencing to guide the treatment of head and neck squamous cell carcinoma.
149. Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors
150. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.